|Articles|June 17, 2010
Phlexglobal Opens First Office in the USA
Advertisement
Specialist global contract research organization Phlexglobal has announced its expansion into the United States with the opening of an office in Carlsbad, California - its first outside of Europe.
Also in the announcement, made at the 46th DIA Annual Meeting in Washington, Phlexglobal, specialists in paper and electronic trial master file solutions, unveiled Aidan Nuttall PhD as US office president.
Heading up Phlexglobal, Inc. Aidan, the co-founder and president of Abingdon Life Sciences and former president of Chiltern International’s US operation, will be working to extend the company’s client base and promote its innovative electronic Trial Master File (eTMF) services including the unique PhlexEview solution.
Phlexglobal’s move to open a US operation follows a sustained period of growth in the UK and Europe, and increasing interest from current and potential US-based client companies. Aidan said: “Phlexglobal has established itself in Europe with a portfolio of niche services and I’m looking forward to extending that to our US clients.
The opening of the US office comes only months after Phlexglobal signed a landmark contract with global biopharmaceutical company UCB to implement a complete TMF management solution in the UK and US worth £12 million over the next five years.
Nicola Murgatroyd, chief executive officer of Phlexglobal, commented: “This has been a really exciting 12 months for us, having secured the ongoing contract with UCB and with our US client base steadily growing, the next logical step was to open a US office.
“I am delighted to have Aidan on board to lead our US operation. His industry experience and contacts will be invaluable to us in promoting and delivering our services to the US clinical research market.”
Also in the announcement, made at the 46th DIA Annual Meeting in Washington, Phlexglobal, specialists in paper and electronic trial master file solutions, unveiled Aidan Nuttall PhD as US office president.
Heading up Phlexglobal, Inc. Aidan, the co-founder and president of Abingdon Life Sciences and former president of Chiltern International’s US operation, will be working to extend the company’s client base and promote its innovative electronic Trial Master File (eTMF) services including the unique PhlexEview solution.
Phlexglobal’s move to open a US operation follows a sustained period of growth in the UK and Europe, and increasing interest from current and potential US-based client companies. Aidan said: “Phlexglobal has established itself in Europe with a portfolio of niche services and I’m looking forward to extending that to our US clients.
The opening of the US office comes only months after Phlexglobal signed a landmark contract with global biopharmaceutical company UCB to implement a complete TMF management solution in the UK and US worth £12 million over the next five years.
Nicola Murgatroyd, chief executive officer of Phlexglobal, commented: “This has been a really exciting 12 months for us, having secured the ongoing contract with UCB and with our US client base steadily growing, the next logical step was to open a US office.
“I am delighted to have Aidan on board to lead our US operation. His industry experience and contacts will be invaluable to us in promoting and delivering our services to the US clinical research market.”
Phlexglobal offers a combination of clinical trial knowledge, document management skills, technical expertise, personnel recruitment and training to the pharmaceutical, biotechnology, medical device, CRO and healthcare industries. Its electronic Trial Master File (eTMF) solution, PhlexEview, is a quality controlled end-to-end process enabling the electronic searching and viewing of centralized TMF documentation from sponsors, subsidiaries, CROs and field-based personnel.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025
- Vabysmo Shows Long-Term Efficacy and Safety in Wet AMD, PCV Patients
September 12th 2025
- Latest NIMBLE Study Results Highlight Progress in gMG Research
September 12th 2025
- ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug Trials
September 11th 2025
Advertisement
Advertisement